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Mucosal T lymphocytes from patients with ulcerative colitis (UC) were
previously shown to display a deficiency in branched N-glycosylation
associated with disease severity. However, whether this glycosylation
pathway shapes the course of the T cell response constituting a
targeted-specific mechanism in UC remains largely unknown. In this
study, we demonstrated that metabolic supplementation of ex vivo
mucosal T cells from patients with active UCwithN-acetylglucosamine
(GlcNAc) resulted in enhancement of branched N-glycosylation in the
T cell receptor (TCR), leading to suppression of T cell growth, inhibition
of the T helper 1 (Th1)/Th17 immune response, and controlled T cell
activity. We further demonstrated that mouse models displaying a
deficiency in the branched N-glycosylation pathway (MGAT5−/−,
MGAT5+/−) exhibited increased susceptibility to severe forms of colitis
and early-onset disease. Importantly, the treatment of thesemicewith
GlcNAc reduced disease severity and suppressed disease progression
due to a controlled T cell-mediated immune response at the intestinal
mucosa. In conclusion, our human ex vivo and preclinical results dem-
onstrate the targeted-specific immunomodulatory properties of this
simple glycan, proposing a therapeutic approach for patients with UC.
T lymphocytes | T cell receptor | adaptive immune response |
branched N-glycosylation | intestinal inflammation
Inflammatory bowel diseases (IBDs), encompassing Crohn’sdisease and ulcerative colitis (UC), are chronic, relapsing, and
life-long inflammatory disorders of the gastrointestinal tract affecting
mainly young populations. The incidence of IBD is increasing
worldwide, and the disease remains incurable, placing a heavy bur-
den on populations by reducing patients’ quality of life and in-
creasing disability (1). The current therapeutic strategies for IBD are
limited by reduced effectiveness, high costs, and/or side effects. This
scenario highlights the urgent need in the clinic of identifying novel
molecular markers capable of being selectively targeted with new and
optimized therapies. Future progress in IBD monitoring and therapy
mostly depends on the identification of key mechanism(s) mediating
intestinal inflammation that could be therapeutically targeted.
The immune system is tightly regulated by glycosylation, through
the addition of carbohydrate structures (glycans) to key molecules
(proteins) involved in innate and adaptive immune responses (2).
The N-acetylglucosaminyltransferase V (GnT-V) is a glycosyl-
transferase encoded by the human MGAT5 gene that catalyzes
the synthesis of β1,6-N-acetylglucosamine (GlcNAc) branched
N-glycans, which are known to play pivotal roles in many glycopro-
teins in cancer (3–6) and also in T cell activity and function (7, 8). In
homeostasis and self-tolerance, T cell activation [via T cell receptor
(TCR) signaling] induces up-regulation of the MGAT5 gene, which,
in turn, leads to GnT-V–mediated glycosylation of the TCR (9).
Consequently, it can promote growth arrest of T cells early, by raising
T cell activation thresholds via limiting TCR clustering at the immune
synapse (and restricting TCR signaling), and, later, by increasing
surface retention of growth inhibitory receptors such as cytotoxic T
lymphocyte antigen-4 (CTLA-4) (9).
In fact, mice deficient in the MGAT5 gene display an increased
susceptibility to autoimmune diseases (7, 10, 11). These mice lacking
GnT-V function (no synthesis of β1,6-GlcNAc branched N-glycan
structures) display an increased TCR clustering and increased T
helper 1 (Th1) differentiation that result in a hyperimmune response
in mouse models of multiple sclerosis (7, 10). Interestingly, in mouse
models of experimental autoimmune encephalomyelitis (EAE) and
type I diabetes, it was shown that supplementation with GlcNAc
induces increased N-glycan branching, through increasing the hex-
osamine pathway, that was associated with inhibition of T cell
growth and differentiation (12, 13), leading to delayed disease
progression. Moreover, N-glycan branching was also found to reg-
ulate T cell development (14). Recently, it was demonstrated that
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branching N-glycans potentiate the differentiation of induced
regulatory (iTreg) T cells over Th17 differentiation (15). Im-
portantly, and in the setting of human immune-mediated disor-
ders, we have recently found that patients with UC exhibit a
deficiency in branched glycosylation (catalyzed by GnT-V) in
mucosal T cells that was associated with disease severity. Patients
with UC who have severe disease showed the most pronounced
defect on branched N-glycans in intestinal T cells, together with
a significant reduction of MGAT5 gene transcription in these
cells (16).
In the present study, and building upon our previous findings in
patients with UC (16), we have evaluated the impact of glycosylation,
particularly the branched N-glycosylation pathway, in the regulation
of the T cell-mediated immune response in patients with UC. We
further explored whether this mechanism could be therapeutically
targeted in vivo through a simple glycan-based strategy. Our results
showed that metabolic supplementation of mucosal T cells, isolated
from patients with active UC, with GlcNAc led to the enhancement
of branched N-glycosylation on the TCR, controlling T cell activation
and function. Preclinical data further demonstrated that GlcNAc
treatment of MGAT5 null or heterozygous mice developing severe
forms of induced colitis significantly controlled disease severity and
progression due to suppression of the intestinal T cell-mediated
immune response, with good clinical effects when GlcNAc was
topically administered by enemas. Altogether, this study highlights
the potential of glycans as novel immunomodulatory agents in IBD,
warranting validation in human clinical trials.
Results
Ex Vivo GlcNAc Supplementation Increased Branched N-Glycosylation
of T Cells from Patients with Active UC. We have previously dem-
onstrated that patients with UC display reduced branched
N-glycosylation on mucosal T cells (16). To assess the ability of
glycans as repairers of the above-mentioned mechanistic defect, we
herein promoted, ex vivo, the hexosamine biosynthetic pathway (SI
Appendix, Fig. S1A) in purified intestinal T cells by metabolic sup-
plementation with GlcNAc. Previous studies showed that supple-
mentation with GlcNAc increases the availability of the substrate
(UDP-GlcNAc) to Golgi enzymes such as GnT-V, enhancing β1,6-
GlcNAc branching N-glycans, particularly in T cells (13). To test this
hypothesis, T cells (CD3+) were isolated ex vivo from both the in-
testinal lamina propria of fresh colonic biopsies and peripheral
blood of patients with UC who have active disease and were sup-
plemented with increasing doses of GlcNAc. Different GlcNAc
concentrations (40 mM, 80 mM, and 100 mM) were tested, and
40 mM did not reveal major alterations compared with nontreated
T cells (SI Appendix, Fig. S1B). The expression of β1,6-GlcNAc
branched N-glycans on colonic T cells was evaluated by flow
cytometry using Phaseolus vulgaris leukoagglutinating (L-PHA) lectin.
We observed a dose-dependent increase of branched N-glycans on
intestinal T cells upon GlcNAc supplementation across different
patients (Fig. 1A). This increased modification with branched
N-glycans was also observed in T cells isolated from peripheral blood
mononuclear cells of patients with active UC displaying FSChigh and
SSChigh light-scattering parameters, characteristic of activated T
lymphocytes (Fig. 1B). The increased expression of β1,6-GlcNAc
branched N-glycans was detected both on CD4+ and CD8+ T cells
(SI Appendix, Fig. S1 C and D). No effects of GlcNAc treatment in
the proportion of CD4+ and CD8+ T cell subsets in the cultures were
observed (SI Appendix, Fig. S1 E and F), supporting that GlcNAc
supplementation leads to a specific modification with branched gly-
cans on T cells in a dose-dependent manner. Importantly, the en-
hancement of branched N-glycans was only observed in T cells from
patients with active UC (Fig. 1C and SI Appendix, Fig. S1G). T cells
from healthy controls and from patients with inactive disease did not
show alterations in the levels of branched glycans upon treatment
with increasing concentrations of GlcNAc (Fig. 1C and SI Appendix,
Fig. S2), possibly due to the higher baseline branching comparing
with patients with active UC. These results were further confirmed by
other technical approaches. Increased expression of β1,6-GlcNAc
branched N-glycans on a band the same size as the TCR β-chain
(TCRβ) after GlcNAc supplementation was also detected by L-PHA
blotting (Fig. 1C) and by TCR immunoprecipitation using lysates of
lamina propria T lymphocytes (LPLs) purified from patients with UC
(Fig. 1D). Interestingly, this increased branching of N-glycans after
GlcNAc supplementation was found to occur in intestinal T cells
from patients with UC with different Mayo subscores (with Mayo
endoscopic subscores 1, 2, and 3) with a trend association with disease
severity, as depicted in SI Appendix, Fig. S1G. The internalization of
externally given GlcNAc was already demonstrated in cell lines (17).
The specific effects of GlcNAc in enhancing branched glycosylation
on T cells from patients with active UC was further demonstrated by
the reversed effects on L-PHA mean fluorescence intensity when
T cells were treated with the N-glycan branching inhibitors kifu-
nensine (KF) and swainsonine (SW) (SI Appendix, Fig. S3) in T cells
from biopsies and blood of patients with active UC. Moreover, the
specific effects of GlcNAc in the enhancement of branched glyco-
sylation in T cells was further validated by supplementation of T cells
from patients with active UC with other glycan types such as D-
mannose, which revealed no impact in branched N-glycan expression
(SI Appendix, Fig. S3). To further validate these observations, we also
performed imaging flow cytometry showing that TCRα/β+ cells dis-
play an increase of fluorescence intensity due to staining with L-PHA
on the cell membrane. This increase was observed in T cells dis-
playing blast-like morphology (Fig. 1 E and E1). Taken together,
these results demonstrate that treating ex vivo T cells from patients
with active UC with GlcNAc promotes the hexosamine biosynthetic
pathway enhancing β1,6-GlcNAc branched N-glycans on the TCR,
and thus restoring the deficiency on branched N-glycans previously
shown in mucosal T cells from patients with UC (16). Next, we have
determined the specificity of this enhancement of β1,6-GlcNAc N-
glycan branching by analyzing the correspondent GnT-V enzymatic
activity. Interestingly, and in line with our previous observations on
MGAT5 gene transcription (16), T cells from patients with active UC
displayed reduced GnT-V enzymatic activity compared with healthy
controls (SI Appendix, Fig. S4). Our results showed that this reduced
GnT-V enzymatic activity of T cells could be significantly recovered
after metabolic supplementation with GlcNAc (Fig. 2A), which fur-
ther supports the effects of GlcNAc in the enhancement of N-glycan
branching mediated by GnT-V. In the N-glycosylation branching
pathway, the β1,6-GlcNAc branched N-glycan catalyzed by GnT-V
can be further extended with polylactosamine structures (ligands for
galectins), which, in turn, can be terminally sialylated (SI Appendix,
Fig. S1A). Our results showed that GlcNAc supplementation of ex
vivo activated T cells led to increased expression of β1,6-GlcNAc
branched N-glycans (as detected by L-PHA lectin) (Figs. 1E and 2 B
and B1) with a trend of increased extension with polylactosamine
structures, as indicated by staining with the Lycopersicon esculentum
agglutinin (LEL) (Fig. 2 B and B1). Additionally, we determined
whether there was a terminal addition of α2,6-linked sialic acid, rec-
ognized by binding of Sambucus nigra agglutinin (SNA), and/or α2,3-
sialic acid, recognized byMaackia amurensis agglutinin (MAL-II). The
results demonstrated a trend of increase in α2,6-linked sialic acid, and
no consistent alterations in α2,3-sialic acid linkages were detected
(Fig. 2 B and B1). Overall, our results support that ex vivo supple-
mentation of T cells from patients with UC with GlcNAc has the
potential to enhance the branched N-glycosylation on T cells,
remodeling the T cell glycoprofile, which is ultimately expected to
have an impact on the regulation of the immune response.
Shaping the T Cell-Mediated Immune Response in UC Through
Increased Branching N-Glycans. After demonstrating the ability of
GlcNAc supplementation to repair the deficiency of branched
N-glycans on ex vivo T cells, we next evaluated its impact on the
modulation of T cell responsiveness. The metabolic supple-
mentation with GlcNAc of ex vivo activated T cells from naive
patients (without therapy) resulted in significant suppression of
their proliferative response to anti-CD3/CD28 mAb stimulation
(Fig. 3 A and A1). In addition, and importantly, the increased
N-glycan branching on T cells resulted in a significant reduction
in the production of the proinflammatory cytokines TNF-α, IFN-
γ, and IL-17A, which are associated with UC pathogenesis (18),
E4652 | www.pnas.org/cgi/doi/10.1073/pnas.1720409115 Dias et al.
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in a GlcNAc dose-dependent manner (Fig. 3B), supporting its effect
on the control of Th1/Th17-type immune responses. The effects of
GlcNAc on the suppression of proinflammatory cytokine production
were found to be independent of cell death and/or decreased T cell
proliferation. After normalization of cytokine concentrations to the
respective T cell proliferation index (index of division), we still ob-
served a reduction in the production of proinflammatory cytokines
(SI Appendix, Fig. S5A). Moreover, the percentage of IFN-γ– and
TNF-α–expressing cells among total CD4+ T cells, evaluated by
intracellular flow cytometry, was decreased upon GlcNAc treatment
(Fig. 3B1). The impact of GlcNAc supplementation on other cy-
tokines, such as TGF-β and IL-10, is not significant (SI Appendix,
Fig. S5 B and C). The specific effects of GlcNAc in suppressing
proinflammatory cytokine production is further confirmed by in-
hibitors (KF and SW), which blocked the regulatory impact of
branched N-glycans in T cell function (SI Appendix, Fig. S6). Next,
we have evaluated the expression of the transcription factors (T-
bet, RORγt, Foxp3, and Gata3) in T cells (CD3+) under ex vivo
GlcNAc treatment. The results showed that GlcNAc supple-
mentation was associated with a reduction in the expression of T-
bet and RORγt, which corroborates the negative impact on the
Th1/Th17-type response (Fig. 3 C and C1). The expression of
Foxp3, a transcription factor associated with regulatory T cells as
well as with human activated T cells (18), was also found to be
reduced upon GlcNAc treatment. To gain insight into the mo-
lecular basis of this modulation of the T cell response through
metabolic supplementation with GlcNAc, we analyzed its impact
on the TCR signaling pathway. We observed that GlcNAc sup-
plementation led to an inhibition of the phosphorylation of
ZAP70 and LAT, thereby hindering T cell activity by controlling
the TCR signaling pathway (Fig. 3D). Additionally, we evaluated
whether GlcNAc supplementation had an impact on T cell apo-
ptosis. Our results showed that T cells from patients with active
UC treated with GlcNAc displayed an increased susceptibility to
apoptosis compared with nontreated T lymphocytes as soon as 3 h
after stimulation (SI Appendix, Fig. S7A). This effect was not seen
in T cells from controls and patients with inactive UC, which
demonstrated no differences, or even a trend to decrease apoptosis,
respectively, at the same time points upon GlcNAc supplementa-
tion. This argues against a putative effect of hyperosmolarity in the
observed increase of apoptosis/cell death in GlcNAc-supplemented
T cells from patients with active UC and in controls (16) (SI Ap-
pendix, Fig. S7A). Treatment with the branched N-glycan inhibitors
(KF and SW) did not reverse the effects of GlcNAc in apoptosis (SI
Appendix, Fig. S7B). At 72 h, a significant decrease in branched
glycosylation levels was observed with KF and SW (SI Appendix, Fig.
S3); however, no differences in the apoptosis were detected (SI
Appendix, Fig. S7B). The percentage of cell death was unchanged or
even higher with SW and KF than with treatment with GlcNAc only
(SI Appendix, Fig. S7B1). Taken together, these data collectively
demonstrate that ex vivo GlcNAc supplementation of T cells from
patients with active UC enhances the branched N-glycans and
resulted in a significant suppression of T cell proliferation and TCR
signaling, as well as controlled Th1/Th17-type immune responses.
Treatment with GlcNAc Reduces Disease Severity and Ameliorates
Clinical Signs of Disease in Mice with Colitis. To determine whether
dysregulation of branched N-glycans on TCR occurs in different
experimental mouse models of colitis, we have evaluated two dif-
ferent chemically induced colitis mouse models, the dextran sodium
sulfate (DSS)-induced and 2,4,6-trinitrobenzene sulfonic acid
(TNBS)-induced models (19), in C57BL/6 wild-type mice. In both
models, colitis was successfully induced, and we have observed a
similar impact on the dysregulation of branched N-glycans in the
TCR (SI Appendix, Fig. S8 A and B), which is in accordance with
our previous observations on human patients with UC (16). The
DSS-induced colitis model was selected as the ideal one to proceed
with, since the rectal induction of disease in the TNBS model would
interfere with the enema administration of GlcNAc. After disease
Fig. 1. Ex vivo GlcNAc supplementation of T cells from patients with UC resulted in increased branching N-glycans. (A and B) CD3+ T cells from patients with
active UC were cultured with different concentrations (millimolar) of GlcNAc, and the fold change of mean fluorescence intensity due to L-PHA staining was
determined by flow cytometry. The scatter plots illustrate the mean ± SEM of five biological replicates. One-way ANOVA using the Newman–Keuls multiple
comparison posttest: *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. (C) Protein lysates of purified CD3+ T cells under GlcNAc treatment were subjected to L-PHA lectin
blotting to evaluate the expression levels of β1,6-GlcNAc branched N-glycans on a protein band corresponding to the migration profile of the TCRβ. WB,
Western blot. (Inset) Linear regression using mean values per treatment condition. (D) Immunoprecipitation (IP) of TCR followed by β1,6-GlcNAc branched N-
glycan recognition with L-PHA. The density of bands is indicated below each band. (E) Imaging flow cytometry analysis (on an ImageStreamX) of L-PHA
membrane distribution on TCR+ cells after GlcNAc supplementation in T cells isolated from blood of patients with active UC. Representative images of ac-
tivated T cells display blast-like morphology showing colocalization (overlaid images) of TCRαβ and L-PHA staining on the cell membrane. (E1) Bars depict the
mean ± SEM of L-PHA staining intensity on gated TCRαβ+ L-PHAhigh cells from three independent experiments. One-way ANOVA using Dunnett’s multiple
comparison posttest: **P ≤ 0.01. In all experiments, results are normalized to the corresponding untreated condition (0 mM).
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onset using 2% DSS, GlcNAc was administered through two different
routes: orally, by supplementing the drinking water with 0.25 mg/mL
GlcNAc, and/or rectally, using 0.5 mg/mL GlcNAc enemas. With
this approach, we assessed the therapeutic effects of GlcNAc
on disease activity and on the control of intestinal inflammation.
The experiment design is summarized in Fig. 4A. Our results
showed that mice with colitis and treated with GlcNAc exhibited
lower body weight loss (Fig. 4B) and significant improvements in
disease activity index (DAI) (Fig. 4C) in comparison to mice with
colitis not treated with GlcNAc (DSS control). Importantly,
whenever animals received GlcNAc topically by enema adminis-
tration (either alone or in combination with oral GlcNAc), the
body weight changes were lower in comparison to animals receiving
only oral GlcNAc. These results suggest that GlcNAc enemas may
have promising topical effects on the control of disease severity
(Fig. 4 B and C, Insets). Accordingly, macroscopic observation of
the colon showed that mice with colitis displayed visible colonic
edema (swelling of the bowel wall) that recovered upon GlcNAc
treatment (SI Appendix, Fig. S8C). In addition, mice with colitis
displayed extensive lymphocytic infiltrates (Fig. 4D, arrowhead)
presenting with CD3+ cells (Fig. 5A) in the intestinal lamina
propria, together with notable alterations of the glandular mor-
phology. Furthermore, these animals also showed a reduced mucus
layer (produced by glycoproteins at the glycocalyx), a natural bar-
rier that confers protection from microbiota, preventing disease
aggressiveness and progression (20). When animals with colitis were
treated with GlcNAc, there was a decrease in the lymphocytic in-
filtrate and an improvement of the glandular architecture (Fig. 4D),
which is compatible with disease remission (21). To further in-
vestigate the relationship between this overall improvement of
disease severity through GlcNAc treatment and the levels of β1,6-
GlcNAc branched N-glycans on LPLs, we performed L-PHA and
CD3 histochemistry in the formalin-fixed, paraffin-embedded
(FFPE) colonic specimens from the different groups of animals
(Fig. 5A). The results showed that induction of colitis was accom-
panied by a notable intestinal lymphocytic infiltrate in the lamina
propria, including CD3-expressing cells that expressed low levels of
branched N-glycans. When mice were treated with GlcNAc, an
increased expression of β1,6-branched glycans in the inflammatory
infiltrate was observed (Fig. 5A, arrowheads). Importantly, the ad-
ministration of GlcNAc also resulted in increased mucus lining,
with augmented expression of branched glycans in glycoproteins in
the superficial mucus layer, which is compatible with disease re-
mission. Afterward, we investigated whether the TCR was partic-
ularly targeted by the observed enhancement of branched N-glycans
in vivo. The results showed that GlcNAc treatment resulted in in-
creased branching glycosylation on intestinal T cells, particularly in
the TCR (Fig. 5 B and B1). To further address the mechanistic basis
of the clinical efficacy of GlcNAc, we have evaluated the impact on
T cell activity and signaling. Interestingly, LPLs from GlcNAc-
treated mice displayed a decrease in the phosphorylation levels of
ZAP70 and LAT that was more pronounced in mice treated with
GlcNAc enemas (Fig. 5C). This result supports control of T cell
activity through GlcNAc treatment, with effective results in topical/
enema administration. Next, the effects of GlcNAc administration
on the expression levels of T-bet, the transcription factor associated
with proinflammatory Th1 cell polarization, were assessed in situ in
the intestinal lamina propria. We have observed abundant cells
expressing T-bet in lymphocytic infiltrates in mice with colitis that
were markedly reduced in GlcNAc-treated mice (Fig. 5D, Insets).
Furthermore, mice treated with GlcNAc revealed a significant re-
duction of IFN-γ production and a trend in the suppression of IL-
17A secretion, further supporting that the enhancement of
branched N-glycans by GlcNAc treatment controls Th1/Th17-type
immune responses in vivo (Fig. 5E). Taken together, our in vivo
results demonstrate a therapeutic effect of GlcNAc in a colitis-
induced mouse model, revealing the immunomodulatory proper-
ties of this agent in the control of intestinal inflammation and,
consequently, in the control of disease severity and progression.
Deficiency in Branched Glycosylation in MGAT5 Null or Heterozygous
Mice Is Associated with Early-Onset Disease and Increased Severity of
Colitis that Is Suppressed by GlcNAc Treatment. To gain insights into
the targeted-specific therapeutic effects of GlcNAc, we used
MGAT5 null or heterozygous mice that display a deficiency in
branched N-glycosylation, mimicking the mechanistic defect de-
scribed in humans (16). The impact on DSS-induced colitis onset
and severity was assessed in MGAT5 heterozygous (+/−, partial de-
ficiency on branched N-glycosylation) and MGAT5 knockout (−/−,
absence of branched N-glycans) mice. Those genotypes represent
intermediate N-glycans and the loss of one branch (β1,6-branching)
of N-glycans, which may mimic mild/moderate versus severe de-
ficiency on branched glycosylation. Our results showed that after
DSS induction, MGAT5 null or heterozygous mice exhibited in-
creased susceptibility to early-onset disease and to severe forms of
colitis. At day 2 after DSS induction, more that 50% of MGAT5−/−
mice developed both mild and moderate forms of colitis compared
with WT mice, which only developed clinical signs of colitis at day
6 postinduction (Fig. 6A). Moreover, at the end of DSS induction
period (day 7), and based on the DAI, we observed increased sus-
ceptibility to severe forms of colitis in MGAT5 null or heterozygous
mice (Fig. 6A). As depicted in the pie chart in Fig. 6A, on day 7,
more than 50% of MGAT5−/− mice exhibited severe forms of dis-
ease (scores ≥3) and 29% of MGAT5+/− mice developed severe
colitis. In contrast, WT mice presented only mild/moderate forms
of the disease. These results reinforce that MGAT5-mediated
branched glycosylation has a strong impact on UC disease onset
and progression.
Afterward, we tested the effect of GlcNAc treatment on the
control of disease severity in mice with the different MGAT5
genotypes. As shown in Fig. 6 B and B1, MGAT5+/− mice with
colitis and treated with GlcNAc presented lower body weight loss
and lower DAI compared with nontreated controls. With regard
to body weight changes and DAI scores, the same tendency was
observed in MGAT5−/− mice treated with GlcNAc (Fig. 6 C and
C1). Due to their higher susceptibility to colitis, nontreated
MGAT5−/− animals were euthanized on day 10 since they
reached the established humane end points. MGAT5−/− mice,
besides developing a much more aggressive disease phenotype,
Fig. 2. Remodeling of the glycosylation phenotype upon metabolic sup-
plementation with GlcNAc. (A) Impact of GlcNAc supplementation on GnT-V
activity was determined using a pool of lysates from treated vs. nontreated
peripheral blood T cells, in three biological replicates of patients with active
UC, from two independent technical experiments. Student’s t test: **P ≤
0.01. (B) Flow cytometry evaluation of glycophenotype of T cells upon
GlcNAc supplementation. (B1) Scatter plot: fold change of MFI due to
staining with each lectin on T cells, in two biological replicates with different
stages of disease severity (Mayo endoscopic scores 1 and 2), from two in-
dependent experiments. Results are normalized to the untreated condition,
which was taken as 1. Student’s t test: *P ≤ 0.05. NS, not significant.
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were also less responsive to GlcNAc, which makes GlcNAc
therapy in these mice more challenging. Nevertheless, the results
in MGAT5+/− and MGAT5−/− mice (Fig. 6 B–D) showed that
even in these mice, treatment with GlcNAc improved clinical
scores compared with the scores of DSS mice. This beneficial
effect was pronounced whenever GlcNAc was administered
topically by enema (single or in combination with oral adminis-
tration), as evidenced by lower body weight loss and lower colitis
scores compared with DSS mice. Interestingly, when GlcNAc
treatment was initiated earlier in disease course of MGAT5−/−
mice, at day 5, when animals started to develop severe colitis, we
observed a decrease of the colitis scores compared with non-
treated diseased animals (DSS), which supports the benefits
of treating these susceptible animals earlier with GlcNAc, as
demonstrated in Fig. 6D.
GlcNAc Treatment of MGAT5 Null or Heterozygous Mice Attenuates
Disease Progression by Controlling Th1/Th17-Type Immune Responses.
MGAT5 null and heterozygous mice showed disorganization of the
glandular architecture and an increase of inflammatory infiltrates in
the colonic mucosa after DSS-induced colitis that was improved
overall upon GlcNAc treatment (Fig. 7A). Notably, the evaluation
of β1,6-GlcNAc branched N-glycan levels on CD3+ LPLs con-
firmed that the induction of colitis was accompanied by decreased
expression of branched N-glycans in LPLs from MGAT5+/− mice
and by the absence of branched N-glycans in MGAT5−/− mice with
induced colitis (DSS) (Fig. 7A). Interestingly, when mice of both
MGAT5 genotypes were treated with GlcNAc, a recovery of β1,6-
branched glycan expression was observed in the intestinal in-
flammatory infiltrate (Fig. 7A, arrowhead) and in the superficial
mucus layer, which is compatible with mucosal healing. The positive
detection of L-PHA staining in MGAT5 null mice upon GlcNAc
supplementation was unexpected, as these mice lack the GnT-V
enzyme. This positive detection was confirmed at the protein level
by L-PHA blot (Fig. 7B and SI Appendix, Fig. S9A). In fact, the
reactivity of L-PHA in MGAT5−/− mice is the lowest, compared
with heterozygous and WT mice, but it is still positive. These ob-
servations may be in line with redundant effects of other GnTs at
the Golgi (22–24) that, within an activated hexosamine pathway,
may compensate for the absence ofMGAT5 by producing the β1,6-
GlcNAc branched glycans, although with a much lower yield of
synthesis, as we have observed. In an attempt to explore the po-
tential compensatory synthesis of β1,6-GlcNAc branched N-glycans
in MGAT5 null mice, interestingly, we have observed that the
MGAT5b gene [a homologous gene of MGAT5a that codifies the
GnT-IX or GnT-Vb enzyme (25)] is apparently up-regulated in
colonic T cells from MGAT5 null mice treated with GlcNAc
compared with control mice (nontreated mice) (SI Appendix, Fig.
S9B). MGAT5 null mice with DSS-induced colitis do not express
MGAT5b. This preliminary evidence suggests GnT-IX/Vb as a
potential candidate that might compensate for the synthesis of β1,6-
GlcNAc branched glycans in MGAT5 null mice. This issue needs
further investigation. We then assessed the enhancement of
branched N-glycans specifically on T cells after GlcNAc treatment.
MGAT5 null or heterozygous mice treated with GlcNAc showed an
enhanced expression of branched N-glycans in the TCR compared
with nontreated diseased animals (DSS) (Fig. 7 C and D). This
effect was highlighted when animals were treated topically with
GlcNAc enemas (Fig. 7 C andD). To explore the mechanistic effects
of GlcNAc treatment in the T cell-mediated immune response, the
Fig. 3. Control of T cell-mediated immune response through enhancing branching N-glycosylation. (A) Purified CD3+ T cells from fresh biopsies of naive
patients with active UC were labeled with CFSE and cultured with GlcNAc treatment. The gated cells in the histograms correspond to the percentage of live
cells. (A1) Bar plot: the mean percentage of effect ± SEM due to GlcNAc supplementation on T cell proliferation in comparison to untreated cells. Results
include four biological replicates. Student’s t test: *P ≤ 0.05. (B) Cytokine profile assessed by flow cytometry in the supernatants from ex vivo T cell cultures
under GlcNAc supplementation. Bar plots: mean fold change ± SEM of cytokine concentrations (picograms per milliliter) in six biological replicates. Student’s t test: *P ≤
0.05; **P ≤ 0.01. (B1) Evaluation of the percentage of IFN-γ– and TNF-α–producing CD4+ T cells treated vs. nontreated with GlcNAc. Bar plots: mean ± SEM percentage
of CD4+cytokine-producing cells in three biological replicates from two independent experiments. Two-way ANOVA with Bonferroni postcorrection: **P ≤ 0.01. (C)
Expression of the transcription factors (TFs) in CD4+CD45+ T cells isolated from patients with UC and analyzed by flow cytometry. Histogram overlays correspond to the
expression of the indicated TFs observed upon GlcNAc supplementation (gray-shadowed histograms depict the respective unstained control). (C1) Bar plots: mean fold
change in TF mean fluorescence intensity ± SEM in two biological replicates, from two independent experiments. Two-way ANOVA with Bonferroni postcorrection:
*P ≤ 0.05; **P ≤ 0.01. (D) Western blot analysis of TCR signaling, p-ZAP70, and p-LAT assessed in T cell lysates from cultures supplemented with GlcNAc. Bar plots:
mean ± SEM fold change of p-ZAP70 and p-LAT densities normalized to tubulin in five biological replicates, from three independent experiments. Student’s t test: *P ≤
0.05. In all experiments, results are normalized to the corresponding untreated condition (0 mM), which was taken as 1.
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impact on TCR signaling was evaluated in MGAT5 null and het-
erozygous mice. An overall decrease of ZAP70 phosphorylation,
indicative of reduced TCR signaling, was detected in colonic T cells
from GlcNAc-treated mice that was evident when GlcNAc was
administered topically (Fig. 7E). This topical effect was particularly
observed in MGAT5−/− mice, where oral treatment did not affect
TCR signaling. The more marked effect achieved through GlcNAc
enema administration suggests that this molecule may be more effi-
ciently taken up by cells in this way, likely by increasing its local
concentration, thus facilitating its entry into the hexosamine path-
way and usage by glycosyltransferases other than GnT-V (SI Ap-
pendix, Fig. S9A) that may redundantly catalyze the branched
N-glycans. These redundant effects need further investigation. Ad-
ditionally, the evaluation of the Th1 proinflammatory response
revealed that GlcNAc treatment in both genotypes was associated
with reduced proportions of cells expressing T-bet in lymphocytic
infiltrates compared with control mice with colitis (Fig. 7F). Nota-
bly, similar to our observations of GlcNAc treatment in T cells from
patients with UC, colonic explants from MGAT5 null or heterozy-
gous mice treated with GlcNAc indicate a trend for IFN-γ sup-
pression, but with a more pronounced effect in reducing IL-17A.
These results further support the impact of GlcNAc treatment and,
consequently, the enhancement of branched N-glycans in control-
ling Th1/Th17-type immune responses also in the IBD in vivo
model (Fig. 7G). Regarding the impact of GlcNAc on regulatory
T cells, no apparent difference in the numbers of FoxP3-expressing
cells was observed at the intestinal lamina propria comparing non-
treated versus GlcNAc-treated mice of MGAT5wt and MGAT5−/−
genotypes (SI Appendix, Fig. S9C). Nevertheless, further studies are
needed to better characterize the regulatory effects of GlcNAc
treatment in the different components of the immune response, such
as in macrophages (SI Appendix, Fig. S9 D and E), as proposed by
previous reports (26), and other T cell populations. Taken together,
these data support the targeted-specific effects of GlcNAc that were
able to repair the deficiency in branched glycosylation on T cells as-
sociated withMGAT5 deficiency, thus controlling progression of colitis.
Discussion
IBD is characterized by a substantial heterogeneity concerning dis-
ease onset, course, response to therapy, and progression to compli-
cations (e.g., hospitalization, need for surgery, cancer) (1). Moreover,
and despite recent advances in IBD therapeutic resources, a high
proportion of patients remain refractory to conventional treatment,
and approximately half of the patients with UC do not achieve
Fig. 5. Colitis-induced mouse model treated with GlcNAc showed increased
branched N-glycosylation associated with suppression of T cell function. (A)
L-PHA histochemistry and CD3 immunohistochemistry. L-PHA lectin reactivity
showed an increased expression of β1,6-branched structures in the intestinal
inflammatory infiltrate (positive to CD3) as well as an increase in mucus
lining in mice treated with GlcNAc enemas (arrowheads). (Magnification:
63×.) (B) Immunoprecipitation (IP) of TCR followed by β1,6-GlcNAc branched
N-glycan recognition in mouse colon, DSS (DSS-induced colitis) vs. DSS + GlcNAc
treatment (Tx). WB, Western blot. (B1) Scatter plot: ratio of densities of L-PHA
reactivity normalized to that of TCR depicted as the mean ± SEM comparing DSS
(n = 2) mice with DSS + GlcNAc Tx (n = 3) mice. Student’s t test: *P ≤ 0.05. (C) TCR
signaling by Western blot analysis of the phosphorylation levels of ZAP70 and
LAT in LPLs. Values of pZAP70 densities normalized to tubulin are indicated. (D)
Immunofluorescence of T-bet in colonic sections of DSS vs. DSS + GlcNAc Tx.
(Insets) T-bet–expressing cells at intestinal inflammatory infiltrate are highlighted.
(Magnification: 20×.) (E) Concentration of IFN-γ and IL-17A in the supernatants of
24-h colonic explant cultures from DSS and DSS + GlcNAc TxMGAT5wt (n = 5)
mice by ELISA. Plots depict the mean ± SEM of two to three animals per
group. Student’s t test: **P ≤ 0.01. NS, not significant.
Fig. 4. Colitis-induced mouse model treated with GlcNAc displays significant
control of disease severity and recovery from clinical signs. (A) Schematic
representation of the in vivo study performed on C57BL/6 mice. (B and C)
Body weight changes and DAI. (B) Effects of GlcNAc on body weight change
(%) comparing DSS control and GlcNAc-treated animals. Graphs depict the
mean ± SEM. Two-way ANOVA with Bonferroni postcorrection: ***P ≤ 0.001.
(Inset) Discrimination of the effects of GlcNAc on body weight change (%)
using different routes of administration. Scatter plots include the mean ±
SEM. One-way ANOVA with Bonferroni postcorrection: *P ≤ 0.05; ***P ≤
0.001. (C) DAI comparing mice with colitis that were untreated with those
that were treated with GlcNAc. Plots depict the mean ± SEM. Two-way
ANOVA with Bonferroni postcorrection: *P ≤ 0.05; **P ≤ 0.01. (Inset) Dis-
crimination of the effect of GlcNAc on colitis scores using different routes of
administration. Plots depict the mean ± SEM. One-way ANOVA with Bon-
ferroni post correction: ***P ≤ 0.001. (D) Representative histological images
(H&E) of colonic samples from mice [normal colon, DSS (DSS-induced colitis),
and GlcNAc treatment (Tx) (DSS + GlcNAc Enema Tx)]. (Magnification: 40×.)
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sustained remission (27). In addition, issues related to side ef-
fects and failure in therapy response highlight the need for more
effective and targeted-specific drugs (28). We have recently
demonstrated that patients with UC exhibit a deficiency in
branched glycosylation on intestinal T cells due to a transcrip-
tional reduction of the MGAT5 gene that accompanied disease
severity (16).
Herein, we uncovered a prominent role for the branched gly-
cosylation pathway in IBD pathogenesis, by shaping the course of
the T cell response. This pathway is thus an attractive target for
novel therapies. Indeed, we have shown here that checkpoints of
T cell immune response in UC could be modulated by metabolic
supplementation with the simple sugar GlcNAc. We showed that
GlcNAc therapy concomitantly increased branched N-glycosylation
on T cells and down-regulated T cell proinflammatory responses
both ex vivo and in vivo. In line with these observations, it was
previously reported that lack of β1,6-GlcNAc branched N-glycans,
by targeted deletion of the locus encoding GnT-V, results in en-
hanced TCR signaling and increased susceptibility to multiple
sclerosis (7, 10). Moreover, and in accordance with our results, the
increase of N-glycan branching through GlcNAc salvage into the
hexosamine pathway was associated with a decreased threshold in
T cell activation and more stable CTLA-4 surface expression, which
resulted in the inhibition of adoptively transferred EAE (7, 13).
The evidence presented here suggests that GlcNAc supple-
mentation of T cells isolated from patients with active UC resulted
in remodeling of the glycophenotype of T lymphocytes through a
marked increase of β1,6-GlcNAc branched N-glycans and an in-
crease of polylactosamine structures, the ligand for galectins (29),
that can then be terminally sialylated, predominantly with α2,6-
sialic acid residues. This glycan reprogramming on T cells was
shown to translate into key immunomodulatory effects in UC.
Importantly, the enhancement of branched N-glycans on T cells
induced by GlcNAc supplementation led to the suppression of
T cell proliferation; inhibition of T cell signaling; reduced pro-
duction of the proinflammatory cytokines TNF-α, INF-γ, and IL1-
7A; and controlled Th1- and Th17-type responses. Both Th
responses have been associated with IBD pathogenesis (30).
Furthermore, these results are in accordance with a very recent
report using mouse T cell cultures, which showed the ability of
GlcNAc to promote iTreg over Th17 differentiation (15).
The glycosylation of T cells can also have an impact on the sus-
ceptibility to cell death (31). Accordingly, treatment of T cells with
GlcNAc induced an increased susceptibility to apoptosis, which is at
the core of different regulatory processes controlling T cell activa-
tion and expansion, thus avoiding exacerbated inflammation (32).
This effect of GlcNAc on apoptosis was dose-dependent and limited
to T cells from patients with active UC (SI Appendix, Fig. S7B). In
agreement, previous reports have shown that extension with poly-
lactosamine structures, which are ligands for galectins (such as
galectin 1), was associated with proapoptotic effects of CD4+ T cells
(31, 33). Nevertheless, and given that treatment with KF and SW did
not reverse the apoptotic effects induced by GlcNAc in the cells of
patients with active UC, it cannot be excluded that factors other
than branching glycans can also contribute to GlcNAc-mediated
regulation of in vitro T cell apoptosis. Importantly, besides the
TCR, the enhancement of branched N-glycosylation can also
modify other receptors like the coreceptors CD4 and CD8, as well
as the growth inhibitory receptor CTLA-4 (7, 10, 22). Moreover,
CD45 and CD25 are also potential targets of branched glycosyl-
ation modification that can further contribute to the regulation of
the T cell-mediated immune response through branching N-
glycans (15, 34). Immunomodulation through GlcNAc-mediated
enhancement of branched glycosylation, as described here, is a
promising therapeutic approach to restore T cell homeostasis in
IBD (SI Appendix, Fig. S10). Indeed, metabolic regulation of T cell
function has been highlighted by recent research (35) and may be
manipulated to reduce T cell-mediated inflammation (15, 36).
The preclinical data reported here provide the proof of concept
supporting such a therapeutic approach in IBD. Deficiency of the
MGAT5 gene was associated with higher susceptibility to severe
forms of colitis and early-onset disease. These data highlight the
prominent role of branched N-glycosylation in the pathogenesis of
IBD, and are in accordance with previous studies on multiple
sclerosis (11). GlcNAc supplementation improved clinical scores
and was associated with a better disease course in mice developing
the most severe disease phenotype (MGAT5−/−). These immune-
suppressive effects catalyzed by GlcNAc were observed by both
oral and enema administration routes, with promising effects when
mice received GlcNAc topically via enemas. This topical effect of
GlcNAc is in line with the ability of GlcNAc to be more efficiently
taken up by the intestinal mucosa, thereby entering directly into the
Fig. 6. MGAT5 null or heterozygous mice develop early-onset colitis and an
increase in disease severity that is suppressed by GlcNAc treatment. (A)
Evaluation of colitis onset and disease severity in MGAT5 null or heterozygous
mice: C57BL/6 WT (n = 14), MGAT5+/− (n = 23), and MGAT5−/− (n = 11) mice.
Active disease was defined when animals showed a DAI of ≥2, and three stages
of severity were defined: mild (≥2 and <2.5), moderate (≥2.5 and <3), and severe
(≥3). Average results of body weight change (B and C) and DAI (B1 and C1) of
MGAT5+/− (n = 23) andMGAT5−/− (n = 9) mice, respectively, randomly distributed
in controls and GlcNAc treatment groups are shown. DSS-induced colitis (DSS) vs.
DSS treated with GlcNAc treatment (DSS + GlcNAc Tx). Animals showing severe
signs of disease were euthanized (†). (B and B1, Insets) Discrimination of the
efficiency of GlcNAc treatment (colitis scores) with different routes of adminis-
tration upon 4 d of treatment. Graphs correspond to the mean ± SEM of
17 animals (three to seven animals per route of administration). Student’s t test
(B and B1) and one-way ANOVA with Bonferroni postcorrection (B and B1, In-
sets): *P ≤ 0.05*; **P ≤ 0.01; ***P ≤ 0.001. Body weight changes of MGAT5−/−
mice treated through different routes vs. nontreated upon 2 d of treatment (C)
and DAI scores of MGAT5−/− mice treated (n = 7) vs. nontreated (n = 2) (C1) are
shown. (C and C1, Insets) Discrimination of the efficiency of GlcNAc treatment
(colitis scores) with different routes of administration upon 3 d of treatment.
(D) Evaluation of the impact of early oral route (O) + enema route (E) GlcNAc
treatment (starting on the second day of disease onset: 5–6 d after DSS in-
duction) on the colitis scores (DAI of animals per group) of MGAT5−/− mice,
comparing DSS (n = 5) with GlcNAc treated mice (n = 4).
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hexosamine pathway to increase branched glycosylation. Intriguingly,
in MGAT5−/−, with the absence of MGAT5/GnT-V, expression of the
β1,6-GlcNAc branched N-glycans detected by L-PHA lectin histo-
chemistry and blotting was positive and slightly increased with GlcNAc
treatment. This unexpected result may be in accordance with the fact
that several glycosyltransferase-deficient mice exhibit no or only mild
phenotypes due to redundancy or compensation of glycan functions. In
fact, several family members of glycosyltransferases are known to be
functionally redundant (37, 38). This potential redundant effect
observed in MGAT5−/− mice treated with GlcNAc might be due to
the fact that other Golgi glycosyltransferases within an activated
hexosamine pathway triggered by UDP-GlcNAc may compensate
for the lack of this specific glycan structure, thereby guaranteeing
immune homeostasis. One of the candidate enzymes is the homol-
ogous GnT-Vb that may compensate for the synthesis of the
branched glycans; however, further studies are needed to clarify this
issue. Similar examples of the redundancy of glycosyltransferases
were described, such as for FUT8-deficient mice (39). Nevertheless,
this redundant effect observed upon GlcNAc supplementation needs
to be further explored.
The clinical effects of GlcNAc were further evidenced by the
decreased frequency of T-bet–expressing cells in colonic mucosa
of treated mice, together with reduced release of the proin-
flammatory cytokine IL-17A of respective colonic explants.
GlcNAc is a naturally occurring amino sugar for which no ad-
verse effects were reported in humans (40). It is available as a
dietary supplement, and oral GlcNAc administration showed no
toxicity in rats (41). Interestingly, 17 y ago, oral GlcNAc was de-
scribed to promote intestinal lining through mucus production in
children with severe treatment-resistant IBD (21). In that study,
eight of the 12 children studied went into clinical remission, which
could have resulted from the immunomodulatory effects of
Fig. 7. GlcNAc treatment of MGAT5 null or heterozygous mice attenuates disease progression by controlling Th1/Th17-type immune responses. (A) Rep-
resentative histological images (H&E) of colonic sections fromMGAT5+/− andMGAT5−/− [normal colon, DSS-induced colitis (DSS), and GlcNAc treatment (DSS +
GlcNAc Tx)] (Magnification: 20×.) DSS mice displayed visible signs of lymphocytic infiltrate in the intestinal lamina propria (arrowheads). L-PHA histochemistry
and CD3 immunohistochemistry of mouse colon from the different groups. (Magnification: 20×.) (B) Evaluation of branching N-glycans on colonic total cell
lysates from MGAT5wt, MGAT5+/−, and MGAT5−/− mice comparing DSS control with GlcNAc Tx enema by Western blot (WB). TCL, total cell lysate. (C) Protein
lysates from LPLs isolated from the colon of MGAT5+/− mice with DSS (colitis) or treated (DSS + GlcNAc Tx) mice were subjected to L-PHA lectin blotting to
evaluate the expression of β1,6-GlcNAc branched N-glycans on the TCR (39 kDa). L-PHA density normalized to tubulin is indicated for each case, and fold
change differences of DSS vs. DSS + GlcNAc Tx are highlighted. (D) Immunoprecipitation (IP) of the TCR in total cell lysates from MGAT5−/− mouse colon
followed by β1,6-GlcNAc branched N-glycan recognition. DSS vs. DSS + GlcNAc Tx with different routes of administration. (E) Analysis of the phosphorylation
levels of ZAP70 in LPL lysates from colon of MGAT5+/− and MGAT5−/− mice. Values of pZAP70 normalized to actin in MGAT5+/− and MGAT5−/− mice are
indicated. (F) Immunofluorescence of T-bet in MGAT5+/− and MGAT5−/− mice comparing normal colon, DSS, and DSS + GlcNAc Tx mice. (Magnification: 20×.)
(G) Concentration of IFN-γ and IL-17A in the supernatants of 24-h colonic explant cultures from DSS and DSS + GlcNAc Tx MGAT5 heterozygous (n = 10) and
null (n = 10) mice by ELISA. Plots depict the mean ± SEM of two to seven animals per group. Student’s t test: *P ≤ 0.05; ***P ≤ 0.001. NS, not significant.
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GlcNAc proposed here. Taken together, the combined evidence
from both ex vivo and preclinical data provides proof of concept
for the therapeutic use of GlcNAc (either alone or in combina-
tion with other antiinflammatory therapies) as a simple immu-
nomodulatory strategy in IBD. Assessment of this strategy in
clinical studies is currently ongoing. Some of the most relevant
properties associated with GlcNAc treatment are the absence of
side effects, low cost, and possibility of being used as a simple
rescue therapy to avoid unnecessary toxic effects and step-up
therapies in IBD.
Materials and Methods
Patient Selection and Colonic Biopsy Collection. Fresh colonic biopsies were
obtained from 75 patients (three patients in remission) diagnosed with UC
and normal controls (n = 3) who underwent a scheduled colonoscopy (2014–
2017) at the Gastroenterology Department of Centro Hospitalar do Porto–
Hospital de Santo António (CHP-HSA), Porto, Portugal. All participants gave
informed consent, and procedures were approved by the Ethics Committee
of CHP/HSA [233/12(179-DEFI/177-CES)].
Isolation of CD3+ T Cells from Fresh Colonic Biopsies and Blood of Patients with
Active UC: Ex Vivo Culture of T Cells. After mechanical dissociation of colonic
biopsies and blood density gradient centrifugation using Lymphoprep, CD3+
T cells (from biopsies and blood) were magnetically sorted using an EasySep
Human T Cell Enrichment Kit (STEMCELL Technologies) following the manufac-
turer’s instructions. CD3+ T cells were cultured for 72 h with anti-CD3 mAb (clone
OKT3) and soluble anti-CD28 mAb (clone CD28.2) (eBioscience). T cell cultures
were supplemented with GlcNAc (Sigma and Wellesley Therapeutics, Inc.).
Imaging Flow Cytometry. Imaging flow cytometry analysis was performed as
previously described (42).
Flow Cytometry. CD3+ T cells were stained with CD4 and CD8 (BD Biosciences)
and fluorescein isothiocyanate (FITC)-conjugated L-PHA (Vector Laboratories),
as well as with cell surface markers (CD4, CD45), intracellular antigens (T-bet,
RORγt, Foxp3, and Gata3), and cytokine intracellular staining (TNF-α, IFN-γ).
Various antibodies used for staining are described in SI Appendix, Table S1.
Proliferation Assay. CD3+ T cells were purified from colonic biopsies and la-
beled with 5-(and-6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)
using a CellTrace CFSE Cell Proliferation Kit (Invitrogen), as described by
Oliveira et al. (43).
Cytokine Production. Supernatants from colonic T cell cultures were analyzed
by flow cytometry using the BD Cytometric Bead Array Human Th1/Th2/Th17
Cytokine Kit (BD Biosciences) following the manufacturer’s instructions.
Human TGF-β1 quantification was performed using ELISA kits (R&D Systems)
according to the manufacturer’s instructions. The supernatants from mouse
colonic explant cultures were concentrated using Amicon Ultra-2 mL Cen-
trifugal Filters (Merck Millipore), according to manufacturer’s instructions.
The levels of IFN-γ and IL-17A (anti-mouse, Ready-SET-Go! kits; eBioscience)
and TNF-α and IL-6 (anti-mouse; Biolegend) were quantified by ELISA,
according to the manufacturers’ instructions.
Western Blot and TCR Signaling. TCR signaling and L-PHA lectin blot analysis
(44), using T cell protein lysates (extracted with radioimmunoprecipitation
buffer), were performed as described by Dias et al. (16). Incubation of
phospho–Zap-70 [Tyr319/Syk (Tyr352)] rabbit mAb and anti–phospho-LAT
(Tyr191) rabbit mAb (Cell Signaling Technologies) was performed. Goat
anti-rabbit IgG-HRP mAb was used as a secondary antibody, and rabbit IgG
antiactin (Santa Cruz Biotechnology) or mouse IgG antitubulin (Sigma) was
used as a loading control.
Immunoprecipitation. TCR immunoprecipitation, using total cell lysates
obtained from mouse colons or from ex vivo human T cell cultures, was
performed as previously described (16).
Glycophenotype. T cells were incubated with biotinylated L-PHA, biotinylated
LEL, biotinylated SNA, or biotinylated MAL-II (Vector Labs). Lectins were
revealed with FITC-conjugated streptavidin.
Apoptosis Assays. Apoptotic cells were identified by flow cytometry, using an
FITC Annexin V Apoptosis Detection Kit I (BD Biosciences), following the
manufacturer’s instructions.
Enzymatic Reaction and HPLC Analysis. The GnT-V enzymatic activity analyses
in T cells from patients with UC and controls were performed as previously
described by Takamatsu et al. (45).
DSS- and TNBS-Induced Colitis and in Vivo GlcNAc Treatment. Colitis was in-
ducedwith DSS in C57BL/6,MGAT5wild-type, heterozygous, and knockoutmice
(kindly provided by Michael Pierce, University of Georgia, Athens, GA) (19). The
TNBS model was also performed using C57BL/6 mice (19). After disease onset,
DSS mice were treated with GlcNAc (Sigma and Wellesley Therapeutics, Inc.)
(12). LPLs were isolated from mouse colon as previously described (16).
Tissue Immunohistochemistry and Immunofluorescence. FFPE colonic tissue
slides were used for H&E staining and for immunohistochemistry with L-PHA
and anti-CD3 mAb as well as Foxp3 and F4/80, as described, respectively, by Dias
et al. (16) and Teixeira et al. (46). For T-bet immunofluorescence, mouse IgG1 T-
bet–specific mAb (clone 4B10; Santa Cruz Biotechnology), goat anti-mouse
Alexa 594 secondary antibody (Invitrogen), and DAPI staining were used.
Real-Time PCR. Total RNA from isolated LPLs was extracted and the quanti-
tative real-time PCR (qRT-PCR) was performed using TaqMan Gene Expression
Assays (Applied Biosystems), as previously described (16). qRT-PCR was carried
out in triplicates for the target geneMGAT5b (Taqman probe: Mm01252571_m1)
and the endogenous control 18S (Hs99999901_s1) (Applied Biosystems) (16).
Statistics. Statistical significance was assessed by one-way or two-way ANOVA
using a Bonferroni’s, Dunnett’s, or Newman–Keuls multiple comparison post-
test and, where appropriate, by an unpaired Student’s t test (two-tailed) using
GraphPad Prism 5. P values of <0.05 were considered statistically significant.
More details can be found in SI Appendix, SI Materials and Methods.
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